Strippoli V, Bruzzese T, Galli R, Simonetti N, Tronci N
Istituto di Microbiologia dell'Universita di Roma, La Sapienza, Italy.
Farmaco Sci. 1988 Jul-Aug;43(7-8):619-25.
The new 3-azinomethyl-rifamycin, SPA-S-565, was shown to exert an effective antibacterial activity in vitro comparable to that of rifampicin. In fact, the antibacterial activity of SPA-S-565 against numerous Gram-positive cocci belonging to Staphylococcus and Streptococcus species as well as against 20 strains of Mycobacterium tuberculosis, was similar to that of rifampicin. In Swiss albino mice intraperitoneally infected with Staphylococcus aureus Oxford strain or Streptococcus pyogenes, the protective activity of SPA-S-565 and rifampicin was quite remarkable, and no significant difference was noted between the two antibiotics. In M. tuberculosis-infected mice treated with the antibacterial agents every seven days, the protection exerted by SPA-S-565 was significantly greater than that exerted by rifampicin.
新型3-氮杂甲基利福平SPA-S-565在体外显示出与利福平相当的有效抗菌活性。事实上，SPA-S-565对众多属于葡萄球菌和链球菌属的革兰氏阳性球菌以及20株结核分枝杆菌的抗菌活性与利福平相似。在经金黄色葡萄球菌牛津菌株或化脓性链球菌腹腔感染的瑞士白化小鼠中，SPA-S-565和利福平的保护活性相当显著，两种抗生素之间未观察到显著差异。在用抗菌剂每七天治疗一次的结核分枝杆菌感染小鼠中，SPA-S-565发挥的保护作用明显大于利福平。
